Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for ...

FDA clears United Therapeutics for human trials of pig-to-human kidney transplants. Trial involves gene-edited pig kidneys ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

Get Our Latest Analysis on United Therapeutics United Therapeutics Price Performance NASDAQ UTHR opened at $351.17 on Friday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month ...

Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

UTHR boasts an average earnings surprise of 4.2%. On a historic basis, United Therapeutics has generated cash flow growth of 10.7%, and is expected to report cash flow expansion of 33.3% this year.